Ralpancizumab (Anti-PCSK9) is a monoclonal antibody targeting selective proprotein convertase subtilisin kexin 9 (PCSK9). It has the potential in hemorrhagic stroke, hypercholesterolemic, dyslipidemia treatment. MW 145.28 KD.